JHJiahong Han

Jiahong Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiahong Han has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Royal jelly fatty acids as emerging anticancer agents: integrative mechanisms and translational perspectives

    by Jie Yi, Isack Ibrahim Mrisho, Elshan Musazade, Wei Li, Jiahong Han, Enbo Cai

    Royal jelly (RJ), a nutrient-rich secretion from the hypopharyngeal and mandibular glands of worker bees (Apis mellifera), has gained significant attention as a natural source of bioactive compounds with therapeutic potential. Among its various constituents, medium-chain fatty acids (MCFAs), notably 10-hydroxy-2-decenoic acid (10-HDA), 10-hydroxydecanoic acid (10-HDAA), and sebacic acid (SA), exhibit potent antioxidant, anti-inflammatory, immunomodulatory, and antimicrobial properties. In recent years, 10-HDA has emerged as the primary anticancer agent in RJ, demonstrating the ability to modulate key oncogenic pathways, including the induction of apoptosis, cell cycle arrest, and inhibition of angiogenesis and metastasis. This review provides a comprehensive analysis of the chemical composition, biosynthetic origin, and extraction techniques of RJ fatty acids (RJFAs), with a critical focus on their molecular mechanisms of anticancer action, including modulation of cell signaling pathways, DNA repair mechanisms, and immune response. We further explore their metabolic stability, bioavailability, and synergistic potential with conventional chemotherapeutics in models of lung cancer, breast cancer, liver cancer, and melanoma. Although promising, current limitations, including challenges in standardization, pharmacokinetics, and formulation, warrant further investigation. Future directions emphasize omics-driven approaches, such as genomics, proteomics, and metabolomics, as well as translational research to optimize the clinical applicability of RJFAs. Collectively, these insights position RJFAs, particularly 10-HDA, as compelling candidates for adjunctive cancer therapy and integrative oncology.

  • Open Access

    A Novel Wogonin Derivative Induces Apoptosis in PC-3M Cells by Targeting Mitochondrial Dysfunction and Activating the ROS-p38/MAPK Pathway

    by Dingrui Liu, Fangfei Liu, Mingjie Song, Fengyan Su, Wei Li, Yan Zhao, Jiahong Han, Enbo Cai

    Current cancer treatments have significant limitations. Designing TPP+-modified, mitochondrial-targeted drugs can improve anticancer efficacy. Although wogonin exhibits antitumor activity, it has drawbacks, including poor solubility and limited distribution. This study designed and synthesized 27 derivatives, including nine novel wogonin triphenylphosphine derivatives that demonstrated in vitro antitumor activity. Mito-WO-8, one of these derivatives, exhibited potent activity against PC-3M cells (IC50 = 3.19 μmol/L), demonstrating 15-fold higher potency than wogonin. Further analysis revealed that Mito-WO-8 accumulates more in mitochondria than wogonin and induces mitochondrial dysfunction, including increased reactive oxygen species, reduced membrane potential, and activation of the MPTP channel. Transcriptome and network analyses revealed that Mito-WO-8 activates the p38/MAPK pathway. Downregulation of p-MKK6 and p-p38, as well as upregulation of DDIT3 and cleaved caspase-3, were validated by Western blot (WB) and quantitative polymerase chain reaction (qPCR). Therefore, Mito-WO-8 enhances mitochondrial enrichment and induces mitochondrial damage. This process is associated with apoptosis and the activation of the ROS-p38/MAPK pathway. Additionally, the study found that Mito-WO-8 exhibits a stronger binding affinity for mitochondrial glycerol-3-phosphate dehydrogenase 2 (GPD2) than the parent compound (−9.6 kJ/mol vs. −6.6 kJ/mol), suggesting a potential interaction with GPD2. This finding establishes a foundation for further investigation into its targeted antitumor mechanism.

  • Open Access

    Effects of Different Drying Methods on the Quality of Forest Ginseng Revealed Based on Metabolomics and Enzyme Activity

    by Junjia Xing, Xue Li, Wenyu Dang, Limin Yang, Lianxue Zhang, Wei Li, Yan Zhao, Jiahong Han, Enbo Cai

    Forest ginseng (FG) is a rare medicinal and culinary plant in China, and its drying quality is heavily dependent on the drying method. This study investigated the effects of traditional hot air drying (HAD) and the self-developed negative-pressure circulating airflow-assisted desiccator drying (PCAD) method on the quality of FG using metabolomics and enzyme activity. The results revealed that the enzyme activities of dried FG were reduced considerably. PCAD preserved higher enzyme activity than HAD. Metabolomics data demonstrate that HAD promotes the formation of primary metabolites (amino acids, lipids, nucleotides, etc.), whereas PCAD promotes the formation of secondary metabolites (terpenoids, phenolic acids, etc.). A change-transformation network was built by combining the metabolites listed above and their biosynthetic pathways, and it was discovered that these biosynthetic pathways were primarily associated with the mevalonate (MVA) pathway, lipid metabolism, phenylpropane biosynthesis, and nucleotide metabolism. It is also believed that these findings are related to the chemical stimulation induced by thermal degradation and the ongoing catalysis of enzyme responses to drought stress. The facts presented above will give a scientific basis for the selection of FG drying processes, as well as helpful references for increasing the nutritional quality of processed FG.


  • Open Access

    The Mechanism of a Novel Mitochondrial-Targeted Icaritin Derivative in Regulating Apoptosis of BEL-7402 Cells Based on the SIRT3 and CypD-Mediated ROS/p38 MAPK Signaling Pathway

    by Zenan Chen, Wei Li, Yan Zhao, Dingrui Liu, Jiahong Han, Enbo Cai

    Tumorigenesis and progression are closely associated with apoptosis and primarily regulated by mitochondria, which are considered major targets for cancer therapy. In this study, twelve novel icaritin (ICT) derivatives were designed and synthesized, four of which were specifically targeted to mitochondria. Biological studies demonstrated that all compounds containing triphenylphosphine (TPP+) exhibited a substantial increase in antitumor activity compared to ICT and control compounds while also exhibiting notable selectivity for tumor cells over normal cells. Among these derivatives, Mito-ICT-4 exhibited the strongest antiproliferative effect, with an IC50 value of 0.73 ± 0.06 μM for BEL-7402 cells, which is 29 times lower than that of ICT, and an IC50 value of 67.11 ± 2.09 μM for HEK293 cells, indicating approximately 33-fold selectivity for tumor cells. High-performance liquid chromatography (HPLC) analysis revealed that Mito-ICT-4 significantly accumulated in the mitochondria of BEL-7402 cells, with the level of accumulation approximately 2.5 times greater than that of ICT. Further investigations demonstrated that upon entering the mitochondria of tumor cells, Mito-ICT-4 downregulated SIRT3 protein expression, disrupted intracellular redox homeostasis, and led to a substantial increase in mitochondrial ROS levels, abnormal CypD-dependent MPTP opening, mitochondrial membrane potential depolarization, and ROS release into the cytoplasm, ultimately triggering ROS-mediated apoptosis in BEL-7402 cells. Transcriptomic analysis identified differentially expressed genes and enriched pathways, highlighting the ROS-mediated p38-MAPK signaling pathway as a key mediator of Mito-ICT-4-induced mitochondria-dependent apoptosis. The effects of Mito-ICT-4 on the expression of key genes (SIRT3, CypD, P-MKK6, P-P38, and DDIT3) were further validated by qRT-PCR and Western blot analysis, with results aligning with transcriptomic data. The novel ICT derivatives synthesized in this study, with mitochondria-targeting functionality, provide a basis for the development of targeted antitumor drugs.

  • Open Access

    Unlocking the Therapeutic Potential of Patchouli Leaves: A Comprehensive Review of Phytochemical and Pharmacological Insights

    by Isack Ibrahim Mrisho, Elshan Musazade, Haobo Chen, Huixuan Zhao, Junjia Xing, Xue Li, Jiahong Han, Enbo Cai

    Plant-based products play an increasingly vital role in the pharmaceutical industry, including Pogostemon cablin (Blanco) Benth. (patchouli), which is notable for its rich history and extensive use in traditional medicine. Patchouli has a longstanding historical use as a remedy for a wide range of health conditions, including colds, fevers, headaches, inflammation, digestive disorders, and insect and snake bites. Comprehensive phytochemical studies have revealed that patchouli leaves contain diverse valuable bioactive compounds, notably patchouli alcohol, β-patchoulene, pogostone, α-bulnesene, and β-caryophyllene. Recent studies have demonstrated that patchouli leaves exhibit various pharmacological properties, including anti-oxidant, anti-inflammatory, antimicrobial, antidepressant, and anticancer effects. Despite robust traditional knowledge, specific therapeutic applications of patchouli leaves require scientific validation and standardization of their bioactive compounds. This review provides a comprehensive overview of the existing literature on the phytochemical composition, pharmacological properties, and underlying mechanisms of action of patchouli essential oil (PEO) and plant extracts obtained from patchouli leaves. It offers detailed insights into potential therapeutic applications, aiming to inform and guide future research across multiple medical disciplines. Ultimately, this review underscores the need for further research to validate and develop the medicinal applications of patchouli leaves, providing a foundation for future healthcare advancements.


  • Open Access

    Widely Targeted Metabolomics Analyses Provide Insights into the Transformation of Active Ingredients During Drying and the Mechanisms of Color Change for Forest Ginseng (Panax ginseng C. A. Mey. cv. Sativi-nemoralis)

    by Junjia Xing, Limin Yang, Lianxue Zhang, Jiahong Han, Enbo Cai

    In this study, we investigated the mechanism of conversion of active components as well as the color change of forest ginseng (FG) during the drying process with the self-developed negative-pressure circulating airflow-assisted desiccator (PCAD) drying method, using a widely targeted metabolomics analytical method based on ultraperformance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS). During the drying process, a total of 1862 metabolites were identified in FG, along with 748 differential abundant metabolites (DAMs). Further analysis of the types and metabolic pathways of the DAMs revealed that both primary and secondary metabolites changed by 50–70% moisture content (MC); secondary metabolites dominated with a 30–50% MC, and primary metabolites dominated with a 10–30% MC, which revealed the differences in the transformation of the active ingredients in the drying process. In addition, the results showed the browning characteristics during the drying process. MC-50 and MC-10 showed the smallest and largest color changes, as well as enzyme activities, compared to the other MCs, respectively. As drying proceeded, browning reactions were mainly related to lipid and nucleotide metabolism and phenylpropane and flavonoid biosynthesis. In conclusion, the present study provides theoretical support for the mechanisms of active ingredient transformation as well as the color change of FG during PCAD drying.


  • Preparation of icariside I and icariside II, an exploration of their protective mechanism against cyclophosphamide-induced bone marrow suppression in mice, and their regulatory effects on immune function

    by X. I. A. O. YANG, S. H. I. Y. U. E. LANG, S. H. U. Q. I. LI, C. H. U. N. L. A. I. JIANG, J. I. A. H. O. N. G. HAN

    This study aimed to prepare icariside I (ICS I) and icariside II (ICS II) from Epimedium koreanum Nakai, explore their protective mechanism against cyclophosphamide-induced bone marrow suppression in mice and determine their regulatory effects on immune function. The results showed that after treatment with ICS I and ICS II, the number of peripheral blood cells in the mice returned to normal. The number of bone marrow nucleated cells (BMNCs) and haematopoietic progenitor cell (HPC) colonies in the ICS I-H and ICS II-H treatment groups increased significantly. The thymus and spleen indices and related cytokine levels in the mice returned to normal. ICS I-H and ICS II-H treatment significantly increased the ratio of Bcl-2/Bax and downregulated the expression of caspase-3 to regulate cell apoptosis. In conclusion, ICS I and ICS II promoted the proliferation and differentiation of bone marrow haematopoietic cells and protected the damaged immune system, and the therapeutic effects of high doses were more significant. Regulating the levels of haematopoietic cytokines, the balance of Bcl-2/Bax, and the inhibition of caspase-3 expression may be the mechanisms of action of ICS I and ICS II against cyclophosphamide-induced bone marrow suppression in mice.